Accelovance, Inc. has acquired Radiant Development, the CRO division of Radiant Research, expanding its range of therapeutic areas. Accelovance has extensive experience with vaccine, infectious disease, and oncology markets, while Radiant has performed studies in areas including cardiovascular, men’s and women’s health, rheumatology, dermatology, oncology and medical device. Financial terms were not disclosed.     Radiant Development has operations in Stuart, FL, Chicago, IL, and Dur...